TSCC patients with a good clinical outcome had a significantly higher number of CD8+ TILs in their tumors (Figure 1), than those with poor clinical outcome, independent of tumor HPV status (mean 50.4 and 12.8 resp., p<0.001), (Table 3 and Figure 2A). The gene discussed is CD8A; the disease is neoplasm.